Safety and efficacy of pulse and daily calcitriol in patients on CAPD: A randomized trial

Nephrology Dialysis Transplantation

Volumn 13, Issue 5, 1998, Pages 1234-1241

  Moe, Sharon M ^a,b   Kraus, Michael A ^a   Gassensmith, Christine M ^a   Fineberg, Naomi S ^a   Gannon, Francis H ^c   Peacock, Munro ^a  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Calcitriol; Calcium balance; CAPD; Dialysis; Hyperparathyroidism; Renal osteodystrophy

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; MALE; ORAL DRUG ADMINISTRATION; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; CALCITRIOL; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PARATHYROID HORMONE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; VITAMIN D;

EID: 0031980583     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.5.1234     Document Type: Article

References (34)

1. Salusky I, Brill J, Oppenheim W, Goodman W. Features of renal osteodystrophy in pediatric patients receiving regular peritoneal dialysis. Semin Nephrol 1989; 9: 37-42
2. Pei Y, Hercz G, Greenwood C et al. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int 1992; 41: 1374-1382
3. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985; 82: 4270-4273
4. Andress DL, Endres DB, Maloney NA, Kopp JB, Coburn JW, Sherrard DJ. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab 1986; 63: 1163-1169
5. Cohen Solal ME, Sebert JL, Boudalliez B et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991; 73: 516-524
6. Berl T, Berns, A, Huffer W et al. 1,23 dihydroxycholecalciferol effects in chronic dialysis. Ann Intern Med 1978; 88: 774-780
7. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B. Oral calcitriol and calcium. Efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34: 840-844
8. Salusky IB, Fine RN, Kangarloo H et al. 'High-dose' calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 1987; 32: 89-95
9. Francis RM, Peacock M. Local action of oral 1,25-dihydroxycholecalciferol on calcium absorption in osteoporosis. Am J Clin Nutr 1987; 46: 315-318
10. Slatopolsky E, Weerts C, Theilan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
11. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard D. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279
12. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism with low-dose intravenous calcitriol. Am J Kidney Dis 1992; 19: 532-539
13. Fischer ER, Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993; 40: 216-220
14. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral vs intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721
15. Levin BS, Song M. Pharmacokinetics and efficacy of pulse oral vs intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7: 488-496
16. 3 pulse therapy. Nephron 1989; 51: 130-131
17. 3 pulse' therapy in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991; 57: 23-28
18. Martin KJ, Ballal HS, Domoto DT, Blalock S, Weindel M. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. Preliminary observations. Am J Kidney Dis 1992; 19: 540-545
19. Schaefer K, Umlauf E, von Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 1992; 19: 460-464
20. Herrmann P, Ritz E, Schmidt-Gayk H et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients. A randomized prospective trial. Nephron 1994,67: 48-53
21. Scanziani R, Dozio B, Bonforte G, Surian M. Effects of calcitriol pulse therapy per os in CAPD patients. Adv Perit Dial 1994; 10: 270-274
22. Juergensen P, Santacroce S, Mooraki A, Cooper K, Finkelstein FO, Kliger AS. Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients. Adv Perit Dial 1994; 10: 259-260
23. Bechtel U, Mucke C, Feucht HE, Schiffl H, Sitter T, Held E. Limitation of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1995; 25: 291-296
24. Felipe C, Miranda B, Selgas R et al. Secondary hyperparathyroidism in CAPD patients. Its suppressibility with high doses of calcitriol. Adv Perit Dial 1990; 6: 238-241
25. Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982; 21: 849-861
26. Weaver CM, Martin BR, Plawecki KL et al. differences in calcium metabolism between adolescent and adult females. Am J Clin Nutr 1995; 61: 577-581
27. Parfitt AM, Drezner MK, Glorieuz FH et al. Bone histomorphometry. Standardization of nomenclature, symbols, and units. J Bone Miner Res 1987; 2: 595-608
28. Weinstein RS. Clinical use of bone biopsy. In: Coe FL, Favus MJ, ed. Disorders of Bone and Mineral Metabolism. Raven Press, New York, 1992; 4555-474
29. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056
30. Mazzaferro S, Pasquali M, Ballanti P et al. Intravenous vs oral calcitriol therapy in renal osteodystrophy. Results of a prospective, pulsed and dose-comparable study. Miner Electrolyte Metab 1994; 20: 122-129
31. Piraino B, Bernardini J, Holley J, Johnston JR, Perlmutter JA, Martis L. Calcium mass transfer in peritoneal dialysis patients using 2.5 mEq/1 calcium dialysate. Clin Nephrol 1992; 37: 48-51
32. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861
33. Qi Q, Monier-Faugere MC, Geng A, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631
34. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844